BIOMARK Laboratories-INDIA

www.biomarklabs.com

TECHNICAL SHEET

B685 PHENYLETHY	PHENYLETHYL BLOOD AGAR BASE (ANAEROBIC)								
Formula	•								
Ingredients:	gms/lit.								
Casein enzymic hydrolysate	15.00								
Papaic digest of soyabean meal	5.00								
Yeast extract	5.00								
Sodium chloride	5.00								
Phenylethyl alcohol	2.50								
L-cystine	0.40								
Vitamin K1	0.01								
Hemin	0.005								
Agar	20.00								
Final pH (at 25°C): 7.5 <u>+</u> 0.2									
Directions :									
Suspend 52.92 ams in 950ml	distilled water Boil to dissolve the medium completely. Sterilize by								

Suspend 52.92 gms. in 950ml. distilled water. Boil to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool to 45-50°C. Aseptically add sterile 50 ml. defibrinated sheep or rabbit blood. Mix well and pour into sterile petri plates.

Principle:

Casein enzymic hydrolysate and papaic digest of soyabean meal and yeast extract provide nitrogen, carbon, sulphur and trace nutrients. Sodium chloride maintains osmotic equilibrium. Addition of Hemin, Vitamin K1 and L-Cystine makes the medium more nutritious and suitable for the growth of fastidious anaerobic bacteria. Phenylethyl alcohol inhibits the growth of gram- negative bacteria particularly Proteus species in the specimens consisting of mixed bacterial population. It has a bacteriostatic action against gram – negative bacteria as it inhibits DNA synthesis.

	bacceria as it iiiii	D.100 D.107 1	5,1161166	0.0.					
QC Tests - (I)Del	nydrated Medium								
Colour:	Yellow								
Appearance :			Homogeneous Free Flowing powder						
(II)Rehydrated m	nedium								
pH (post autoclaving/heating):			7.5 ± 0.2						
Colour (post autoclaving/heating):		a) Basal Medium : Yellow							
		b) With addition of 5% v/v blood. : Cherry red							
Clarity (post autoclaving/heating):		a) Clear to slightly opalescent							
		b) Opaque							
(III)Q.C. Test M									
Cultural chara	cteristics observe	ed after 4	8- 72 h	ırs. (Lo	nger if nece	ssary) at 35-37°C	C, in an anaerobic		
condition.									
	RGANISM (ATCC)			GROWT					
	Bacteroides fragilis (25285)			Good -	luxuriant				
Clostridium perfringens (13124)			G	Good -	luxuriant				
Clostridium butyricum (9690)				Good – luxuriant					
Clostridium sporogenes (11437)			G	Good – luxuriant					
Proteus mirab	Proteus mirabilis (25933)			Fair – good					
Staphylococcu	Staphylococcus aureus (25923)				None – poor				
Precautions:	1. For Laborator								
	2. Follow proper	, establisl	ned laboratory procedures in handling and disposing of						
	infectious materials.								
Limitations :	, , , , , , , , , , , , , , , , , , , ,								
	encountered that fail to grow or grow poorly on this medium.								
Use :	For selective isolation and cultivation of fastidious anaerobic bacteria.								
Storage :	Dehydrated medium and prepared medium – Between 2 to 8°C.								
Packing:	500 gm. bottle								
Product profile:	Reconstitution Quantity on Preparation (pH (25°C)	Supplement	Sterilization		
			ion (50	00g)					
B685 52.92g/l 9.4		9.	9.448L		7.5 ± 0.2	defibrinated	121°C / 15 minutes		
					sheep or rabbit				
						blood			

Refer disclaimer Overleaf

BIOMARK Laboratories-INDIA www.biomarklabs.com TECHNICAL SHEET

Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related BIOMARKLABORATORIES publications.

The information contained in this publication is based on our in-house studies and market performance and is to the best of our knowledge true and accurate. BIOMARK LABORATORIES reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.

Page 02 of 02

Rev: December 2020